Buchumschlag

O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma

Gene silencing of O6-methylguanine-DNA methyltransferase (MGMT) by promoter methylation improves the outcome of glioblastoma patients after combined therapy of alkylating chemotherapeutic agents and radiation. The purpose of this study was to assess the frequency of MGMT promoter methylation in soft...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jakob, Jens (VerfasserIn) , Hille, Maren (VerfasserIn) , Sauer, Christian (VerfasserIn) , Ströbel, Philipp (VerfasserIn) , Wenz, Frederik (VerfasserIn) , Hohenberger, Peter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 30 October 2012
In: Radiation oncology
Year: 2012, Jahrgang: 7
ISSN:1748-717X
DOI:10.1186/1748-717X-7-180
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/1748-717X-7-180
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/1748-717X-7-180
Volltext
Verfasserangaben:Jens Jakob, Maren Hille, Christian Sauer, Philipp Ströbel, Frederik Wenz and Peter Hohenberger
Beschreibung
Zusammenfassung:Gene silencing of O6-methylguanine-DNA methyltransferase (MGMT) by promoter methylation improves the outcome of glioblastoma patients after combined therapy of alkylating chemotherapeutic agents and radiation. The purpose of this study was to assess the frequency of MGMT promoter methylation in soft tissue sarcoma to identify patients eligible for alkylating agent chemotherapy such as temozolomide.
Beschreibung:Published 30 October 2012
Gesehen am 06.07.2018
Beschreibung:Online Resource
ISSN:1748-717X
DOI:10.1186/1748-717X-7-180

Ähnliche Einträge